Proprotein convertase subtilisin/kexin type 9 in the dyslipidaemia of patients with axial spondyloarthritis is related to disease activity
Authors:
- Laura de Armas-RilloLALaura de Armas-Rillo
- Juan C Quevedo-AbeledoJQJuan C Quevedo-Abeledo
- Antonia de Vera-GonzálezAVAntonia de Vera-González
- Alejandra González-DelgadoAGAlejandra González-Delgado
- Alejandro Jimenez-SosaAJAlejandro Jimenez-Sosa
- Miguel A González-GayMiguel A González-Gay
- Iván Ferraz-AmaroIFIván Ferraz-Amaro
Open Access
- 9 December 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 60 (5) , 2296-2306
Abstract
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that regulates cholesterol metabolism and has been linked to cardiovascular (CV) risk. The purpose of the present study was to examine whether PCSK9 levels are related to abnormalities in the lipid profile and the development of atherosclerosis that occurs in patients with axial SpA (axSpA). We performed a cross-sectional study that encompassed 545 individuals; 299 patients with axSpA and 246 statin use–matched controls. PCSK9 and standard lipid profiles were analysed in patients and controls. Carotid intima-media thickness (cIMT) and carotid plaques were assessed in patients. A multivariable analysis, adjusted for standard CV risk factors, was performed to evaluate the influence of PCSK9 on axSpA-related dyslipidaemia and subclinical carotid atherosclerosis. Total cholesterol, high-density lipoprotein and low density lipoprotein cholesterol, lipoprotein (a) and apolipoprotein A1 were significantly lower in axSpA patients than controls. PCSK9 serum levels [β coefficient −44 ng/dl (95% CI −60, −27), P = 0.000] were also downregulated in axSpA patients after fully multivariable adjustment. ASDAS-CRP was found to be independently and significantly related to PCSK9 [β coefficient 10 ng/dl (95% CI 1, 18), P = 0.023] after analysing fully adjusted models that took age, sex and the rest of the lipid profile molecules into account. Whereas patients taking prednisone showed higher serum levels of PCSK9 [55 ng/ml (95% CI 24, 8), P = 0.001], those under anti-TNF-α therapies exhibited lower levels [β coefficient −26 ng/ml (95% CI −43, −9], P = 0.003]. PCSK9 is downregulated in patients with axSpA. Disease activity is positive and significantly related to PSCK9. Anti-TNF-therapy yields a reduction in PCSK9 serum levels.Keywords
All Related Versions
Funding Information
- Spanish Ministry of Health
- Subdirección General de Evaluación y Fomento de la Investigación
- Plan Estatal de Investigación Científica y Técnica y de Innovación
- Fondo Europeo de Desarrollo Regional -FEDER (Fondo de Investigaciones Sanitarias (PI17/00083)
This publication has 37 references indexed in Scilit:
- Proprotein convertase subtilisin/kexin type 9 (PCSK9): From structure–function relation to therapeutic inhibitionNutrition, Metabolism and Cardiovascular Diseases, 2011
- To Match or Not to Match in Epidemiological Studies—Same Outcome but Less PowerInternational Journal of Environmental Research and Public Health, 2010
- The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selectionAnnals of the Rheumatic Diseases, 2009
- Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitisAnnals of the Rheumatic Diseases, 2009
- Mannheim Carotid Intima-Media Thickness Consensus (2004–2006)Cerebrovascular Diseases, 2006
- Increased disease activity is associated with a deteriorated lipid profile in patients with ankylosing spondylitisAnnals of the Rheumatic Diseases, 2006
- Sequence Variations inPCSK9,Low LDL, and Protection against Coronary Heart DiseaseNew England Journal of Medicine, 2006
- Cardiovascular risk parameters in men with ankylosing spondylitis in comparison with non-inflammatory control subjects: relevance of systemic inflammationClinical Science, 2005
- Post-transcriptional Regulation of Low Density Lipoprotein Receptor Protein by Proprotein Convertase Subtilisin/Kexin Type 9a in Mouse LiverJournal of Biological Chemistry, 2004
- The moderator–mediator variable distinction in social psychological research: Conceptual, strategic, and statistical considerations.Journal of Personality and Social Psychology, 1986